Pfizer CDR CAD Hedged (PFE) Share Price

Pfizer Inc. will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February 13-15 in San Francisco, California. Data from more than 20 company-sponsored, investigator-sponsored, and collaborative research abstracts, including five oral presentations, highlight advancements in developing new standards of care within prostate and bladder cancer across the company’s core scientific modalities, including small molecules and antibody-drug conjugates.

https://www.stocktitan.net/news/PFE/pfizer-to-showcase-advancements-across-genitourinary-cancers-at-asco-4m71mveugfbl.html

73.9% post covid vax deaths found directly linked

To vaccination on autopsy

data reported from the largest autopsy survey

phillip.altman
Nov 19, 2024

Scientists estimate that the COVID vaccine saved 3 million lives and prevented 18 million hospitalizations.

President Trump called it "one of the greatest miracles of the ages."

RFK Jr. asked the FDA to revoke the emergency use of vaccines.

$MRNA
$PFE

https://x.com/SenSanders/status/1884991168460534022?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1884991168460534022%7Ctwgr%5E41efa3783bf583914279bce85e9325050c2fc862%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Fwww.thedailybeast.com%2Fbernie-sanders-corners-robert-f-kennedy-jr-did-covid-vaccine-save-lives%2F

https://www.thedailybeast.com/bernie-sanders-corners-robert-f-kennedy-jr-did-covid-vaccine-save-lives/

But newbies look as well, Moderna's killer jab is worse than fuzzy Pfizers. What's going on here?
I expect Pfizer will hit Moderna hard with this info... or not? Why not?
https://kirschsubstack.com/p/breaking-official-czech-record-level?publication_id=548354&post_id=156125860&isFreemail=true&r=x7hm&triedRedirect=true


Now you know part of the real story. Who is protecting who?

These are turbulent times and to be wary and cautious may not be a bad idea.
https://dailynewscycle.com/pfizer-to-pay-60m-in-false-claims-settlement-for-drug-kickbacks-doj-announces/
For any newbies, Pfizer has not a great reputation.

trading just under 9 times forward earnings estimates right now$$$$$$$$

Pfizer avoids board nominations from Starboard as proxy fight rolls on

https://www.fiercepharma.com/pharma/pfizers-board-left-untouched-annual-meeting-proxy-fight-starboard-rolls-bloomberg

Trump HHS secretary nominee RFK Jr to stress he's not 'anti-vaccine' at confirmation hearing
And in his opening statement at his confirmation hearing, Kennedy will spotlight that "all of my kids are vaccinated, and I believe vaccines have a critical role in healthcare."

https://www.foxnews.com/politics/scoop-trump-health-secretary-nominee-rfk-jr-stress-confirmation-hearing-hes-not-anti-vaccine

PFE will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open.

It's all about right and wrong. It is coming down to that. PFE will pay the piper.

New era has emerged. Let's see how all this plays out. The past has a way of catching up if overlooked.

Pfizer would be smart to somehow make amends for past mistakes in regards to mRna and continue on their
path to cutting out on unneeded collaborations. My price target for re-entering on the long side is $22-24 for
purposes of flipping only. I always hold back a few shares just in case. New personnel at the FDA is not going
to make things easier as we enter into the new year.

https://www.benzinga.com/insights/analyst-ratings/25/01/43281053/pfizer-stock-a-deep-dive-into-analyst-perspectives-6-ratings
Where it goes nobody knows.

Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium


https://www.pfizer.com/news/press-release/press-release-detail/pfizer-showcase-advancements-across-genitourinary-cancers?cid=tw_pbg_onco_asco-gu-2025_0125&ttype=tw&linkId=729229623

News https://www.businesswire.com/news/home/20250124736884/en/Pfizer%E2%80%99s-BRAFTOVI%C2%AE-Combination-Regimen-Demonstrates-Improved-Response-in-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer

I anticipate a deal getting struck with someone just prior to or at 12 week top line data read out. I have seen many cases where acquisition occurs prior to FDA approval. Arena Pharmaceuticals (Acquired by Pfizer in 2022) - Arena had a strong focus on immune-inflammatory and CNS-related disorders. Etrasimod, a drug for immune-inflammatory diseases, was a key focus, though Pfizer valued the potential across multiple therapeutic areas. Acquisition Price: $6.7 billion.

Going to be interesting.

Good idea, moms. We have both MNMD and PFE in our portfolios. PFE's expensive acquisition of SGEN(very profitable for us) has been slow to bring enough revenue to the balance sheet to solve PFE's problem being termed a laggard in pharma-land. HLS in Canada terminated a contract with PFE that involved its marketing of AMRN's Vascepa to Canadian GPs, a contract that I had hoped would evolve into PFE acquiring our 225k shares of AMRN by now. PFE CEO Bourla was at DAVOS this past week. We should see whether any deals were struck shortly, I think.

Time will tell
So I ask you. Would you be curious to know .....
A whole lot of so called professionals need to go to jail... or worse.
https://kirschsubstack.com/p/breaking-ican-acquires-critical-fda?publication_id=548354&post_id=155479991&isFreemail=true&r=x7hm&triedRedirect=true Certain protective laws

Were reversed

Immunity

Being one

Accountably

Coming to a theater

Near you

they need to do something good to turn the ship around. the company can certainly look forward to more scrutiny now that there is a new sheriff in town.

PFE raises $3.1B cash by paring HLN stake (as reported yesterday by Bloomberg). After the sale PFE’s HLN stake is reduced from 15% to 7.3%, which means that PFE has another (roughly) $3B source of capital whenever it wants.

This is a long way from where it once was. Yet the company is hemorrhaging. Still they up the dividend to slow the bleeding.
This is a long way from over. The biggest scam in world history just won't go away.
https://givemefive.news/dod-ignored-herd-immunity-data-before-vaccine-mandate/

has announced that it will be paying its dividend of $0.43 on the 7th of March, an increased payment from last year's comparable dividend. This makes the dividend yield 6.5%, which is above the industry average

$PFE

so it seems

is that in competition with Keytruda?

FDA Mandates Nerve Damage Warnings for 2 RSV Vaccines

Respiratory syncytial virus (RSV) activity is currently deemed to be ‘very high’ in many parts of the United States, according to CDC.

By Naveen Athrappully
1/9/2025 Updated: 1/10/2025

The U.S. Food and Drug Administration (FDA) ordered two respiratory syncytial virus (RSV) vaccine manufacturers to include a potentially paralytic side effect warning related to nerve damage on product labels.

The manufacturers, GSK and Pfizer, manufacturing Arexvy and Abrysvo vaccines respectively, must now include a warning stating a risk of Guillain-Barre syndrome (GBS) following vaccination, according to a Jan. 7 statement from the agency.

GBS is a rare disorder in which the immune system ends up damaging nerve cells, which leads to weakness in the muscles and potential near-total paralysis, depending on severity.

RSV is a common respiratory virus that infects the throat, nose, and lungs, and typically spreads during fall and winter seasons. Infected people can experience symptoms similar to that of a common cold such as a runny nose, congestion, sneezing, and coughing.

The FDA said the following statement is to be included in the Warnings and Precautions section of the two vaccines: “The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with Abrysvo” or with “Arexvy” for that vaccine.

Arexvy is used by people aged 50 and older to deal with lower respiratory tract disease caused by RSV, while Abrysvo has been approved for use in adults aged 18 and above.

The labeling requirement follows an observational study conducted by the FDA.

In the study, the agency found there was an “increased risk of GBS during the 42 days following vaccination, with an estimated 9 excess cases of GBS per million doses of Abrysvo, and an estimated 7 excess cases of GBS per million doses of Arexvy administered to individuals 65 years of age and older.”

However, despite these results, the FDA determined that “the benefits of vaccination with Abrysvo and Arexvy continue to outweigh their risks.”

According to the U.S. Centers for Disease Control and Prevention (CDC), early symptoms of GBS can include feelings of weakness and tingling.

“People with GBS usually first feel these symptoms in both legs. Then, they might feel these symptoms in their arms and upper body,” it said. “Symptoms can progress over hours, days, or weeks.” The weakness keeps increasing until people are unable to use certain muscles.

“People with GBS need to be hospitalized,” the agency said. “Most people start to recover 2–3 weeks after symptoms start. Recovery may take as little as a few weeks or as long as a few years. Most people recover fully, but some have permanent nerve damage. Some people have died from GBS.”

The Epoch Times reached out to GSK and Pfizer for comment.


RSV Vaccine Usage and Risks

The RSV vaccine label update comes as the overall respiratory illness activity in the United States is deemed to be at a “high” level, with RSV activity being “very high in many areas of the country, particularly in young children,” according to the CDC.

“Emergency department visits and hospitalizations are highest in children and hospitalizations are elevated among older adults in some areas.”

The agency recommends all babies be protected from RSV by either vaccinating mothers or by giving an antibody to the infant.

Even if the mother is not at high risk for severe RSV, the vaccination is important since the pregnant woman will “pass the protection” to her baby, the CDC said. “It takes two weeks to develop protection (antibodies) and for protection to pass on to your baby.”

This protection lasts for the first six months of the infant’s life “while they are at highest risk of severe RSV.”

Pregnant women who have already taken an RSV vaccine during a previous pregnancy are not recommended to take it again. Instead, the baby should get nirsevimab, an antibody.

CDC recommends antibodies to “all babies younger than eight months of age born to mothers who did not receive a maternal RSV vaccine (Pfizer’s Abrysvo) during pregnancy.”

For older adults, the CDC advises vaccination for 60 to 74-year-olds who are at increased risk of severe RSV and for all individuals aged 75 and above.

However, the agency warns that vaccination could result in certain adverse events. “Side effects such as pain, redness, and swelling where the shot is given, fatigue, fever, headache, nausea, diarrhea, and muscle or joint pain may occur after you get an RSV vaccine.”

“These side effects are usually mild. Patients who have experienced these symptoms when getting other vaccines might be more likely to experience them after getting an RSV vaccine,” it said.

Epoch Times
Subscription necessary to read on site

if approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population

More phuzzy phyzer prhoblems https://www.theepochtimes.com/health/fda-mandates-nerve-damage-warnings-for-2-rsv-vaccines-5789027?src_src=healthnoe&src_cmp=health-2025-01-10&est=AAAAAAAAAAAAAAAAdbAmeh0exsTo9bIGsWoXCLt3DMv%2BeZd%2FEugtIdyHPONOLA%3D%3D

Create a problem

Time reaction

Solve problem

Media controls

The agenda

Who controls

The media

Getting

Close

Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda

https://www.biospace.com/drug-development/pfizers-subcutaneous-pd-1-blocker-aces-phase-iii-in-bladder-cancer-carves-niche-versus-keytruda

$PFE One good bullish news. 

Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with Bacillus Calmette-Guerin as induction therapy with or without maintenance in patients with BCG-naive, high-risk non-muscle invasive bladder cancer.

In terms of bladder cancer, market size is almost 4b in 2023. This is growing and expected to be  5.5b.

At least few dollar worth asset for the stock. 
Thank you very much for the hard work PFE.

Why did Pfizer stop testing on animals

What about human testing

What are the ingredients?

In the next round

Of vaccines

Vexari, any questions???

PFE on fire! Market sees right through the nonsense...  ST target: $30

keep digging mister propaganda: https://petermcculloughmd.substack.com/p/new-study-covid-19-mrna-injections?publication_id=1119676&post_id=154280211&isFreemail=true&r=x7hm&triedRedirect=true

Cleveland Clinic

Nope...

Nope....

Interesting

To say the least

Dive bomber

In and out

https://www.statista.com/statistics/1318652/covid-vaccine-lawsuits-industry/

yes, it will get better after bankruptcy. I plan on buying in at that time or instruct my grand kids to do so.

why no answer? perhaps mr. biotick works for pfizzer.

How many people get it? The spike protein stays in the body and continues to do damage as you age.
Do investors think this is going away any time soon especially now that some real honest folks are about
to run the show? Tik Tok
https://petermcculloughmd.substack.com/p/catastrophic-neurological-and-psychiatric?publication_id=1119676&post_id=154201714&isFreemail=true&r=x7hm&triedRedirect=true

Why would that be?
Complete horse hockey..

Complete horse hockey..

The bird

Is a metamorphical germ

Eating

Dead cell debris

Can not catch something that doesn't exist

Facts don't lie

Open to board discussion

Yep, otherwise they would not be cutting out even some of the most promising collaborations. They are going to have scrap others too in order to stave off bankruptcy possibility in the near future with the pending and growing lawsuits. Other surprises may be waiting too in the form of new and real scrutiny by RFKjr
and the new FDA commissioner. Things are looking ugly and Pfizer is going to pay the consequences for cheating the system, withholding data, and corrupt political collaborations. Not good Pfizer. Looking for investor lawsuits to gain strength.
https://www.businesswire.com/news/home/20241230895593/en/Sangamo-Therapeutics-to-Regain-Full-Rights-to-Hemophilia-A-Gene-Therapy-Program-Following-Pfizer%E2%80%99s-Decision-to-Cease-Development-of-Giroctocogene-Fitelparvovec

imo...

Wikipedia • Coronavirus disease 2019 is a contagious disease caused by the coronavirus SARS-CoV-2. The disease spread worldwide, resulting in the COVID-19 pandemic.
The symptoms of COVID-19 can vary but often include fever, fatigue, cough, breathing difficulties, loss of smell, and loss of taste.

Like a snake bit me...... PFE



PFE


(shivering)


IHuser

Yup, this horseshit is being pumped by Wall Street crooks, cooking the books. It's over for big pharma.

Eli Lilly and Company & Pfizer Inc. are a disaster in the making.

When financial guidance

Is based on a lie

Where does one go

From there

They knew what they were doing

Nothing can stop

What is coming

imo...you are postulating and swaying perception without addressing the science or patents for insured improved health... yea that's because.. I have the market on my side....especially the women now.....and this pos is a done issue stick a fork in it and go play in traffic.....-look at the share price now blue boy ~


PFE





IHuse4